Publications

Filters
April 12, 2022

The WEE1 inhibitor Debio 0123 enhances the efficacy of standard of care DNA damaging agents in lung cancer models

Read more
April 11, 2022

A novel antibody drug conjugate linker enabling production of ADCs with high drug to antibody ratios and fast payload release…

Read more
April 11, 2022

The antibody-drug conjugate GENA-111 conjugated to auristatin F shows therapeutic potency in BCAM positive epithelial cancer

Read more
November 1, 2021

Automated Solid Phase Extraction of Triptorelin using Andrew+ Pipetting Robot for Bioanalytical LC-MS/MS Quantitation

Read more
June 12, 2021

Safety and efficacy of CD37-targeting naratuximab emtansine plus rituximab in diffuse large B-cell lymphoma and other Non-Hodgkin’s B-cell lymphomas –…

Read more
March 23, 2021

Is CD37-targeted therapy a viable alternative in the treatment of diffuse large B-cell lymphoma? Interviews with two key opinion leaders

Read more
March 18, 2021

Antimicrobial activity of the new FabI inhibitor Afabicin desphosphono against intraosteoblastic Staphylococcus aureus

Read more
September 19, 2020

3-Years follow-up results of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus Debio 1143 (xevinapant) or placebo in…

Read more
September 17, 2020

First-in-Human phase 1 study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced…

Read more